Background: Reset osmostat (RO) occurs in 36% of patients with syndrome of inappropriate antidiuretic hormone secretion (SIADH) and is not often considered when evaluating hyponatremic patients. Patients with RO are not usually treated, but recent awareness that symptoms are associated with mild hyponatremia creates a therapeutic dilemma. We encountered patients with hyponatremia, hypouricemia and high urine sodium concentration (UNa), who had normal fractional excretion (FE) of urate and excreted dilute urines that were consistent with RO. We decided to test whether a normal FEurate in nonedematous hyponatremia irrespective of UNa or serum urate would identify patients with RO. Methods: We determined FEurate in nonedematous hyponatremic patients. A diagnosis of RO was made if urine osmolality (Uosm) was <200 mOsm/kg in a random urine. We performed a modified water-loading test in patients with a normal FEurate whose random Uosm was >200 mOsm/kg. Results: All nonedematous hyponatremic patients with FEurate of 4%-11% had RO, as determined by Uosm <200 mOsm/kg on a random urine collection in 8 patients, or after a modified water-loading test in 6 patients. Plasma antidiuretic hormone (ADH) in 4 patients was undetectable at <1 pg/mL during water-loading. Nine patients had baseline concentrated urine, 12 had UNa >20 mmol/L, 9 were hypouricemic, yet all had a normal FEurate. Comorbidities were similar to those reported in RO. Conclusions: RO, a benign form of SIADH, occurs commonly. A normal FEurate in a nonedematous hyponatremic patient is highly suggestive of RO. Determining FEurate is superior to serum urate. The therapeutic dilemma for RO must be resolved.
IntroductIon
Hyponatremia due to a reset osmostat (RO), a syndrome of unknown etiology and designated as type C syndrome of inappropriate antidiuretic hormone secretion (type C SI-ADH), occurs in 36% of patients with SIADH (1). It is not often considered, in part because of the lack of simple diagnostic criteria. An accurate diagnosis can be beneficial because the hyponatremia is usually mild and unlikely to decrease progressively as in other subtypes of SIADH. RO is characterized by euvolemia; normal renal, adrenal and thyroid function; hyponatremia resulting from antidiuretic hormone (ADH) stimulation at a lower plasma osmolality or a reset osmostat, having a reasonably normal diluting and concentrating capacity of urine, and maintaining normal sodium balance without correction of the hyponatremia (2) . Because the hyponatremia in RO is mild, does not progress below the osmolality at which the osmostat has been reset and is unresponsive to different therapeutic regimens, it is common practice not to treat the hyponatremia of RO (3) . However, the awareness that symptoms are attributed to mild hyponatremia has caused many to recommend treating most or all hyponatremics, thus creating a therapeutic dilemma for RO (4) (5) (6) (7) (8) (9) (10) . We utilized elevations in fractional excretion of urate (FEurate) to assess patients with hyponatremia, especially to differentiate SIADH from cerebral or, preferably, renal salt wasting (RSW) (11) (12) (13) (14) . We encountered patients with hyponatremia, normal FEurate and randomly collected dilute urines that were consistent with RO and inconsistent with the frequency with which FEurate is increased in SIADH and RSW. We decided to test whether a normal FEurate would be an indicator of RO (15) (16) (17) (18) (19) (20) . This approach identified 14 cases of RO over a short period of time. We conclude that a normal FEurate in a nonedematous hyponatremic patient is highly suggestive of RO.
Methods
All subjects were recruited from Winthrop-University Hospital and outpatients. Based on our realization that a FEurate of 4%-11% might be a potential marker of RO, we used this single criterion to identify cases of RO, regardless of urine sodium concentration (UNa) or presence or absence of hypouricemia (serum urate <4 mg/dL). The diagnosis of RO was made if the urine osmolality (Uosm) was <200 mOsm/ kg in a random urine collection or after a modified waterloading test in those patients with Uosm >200 mOsm/kg. Although a Uosm to plasma osmolality (Posm) ratio of <1 would fulfill the definition of a dilute urine and possibly RO, we arbitrarily used a Uosm of <200 mOsm/kg to arrive at a more convincing diagnosis of RO. After obtaining a signed informed consent in accordance with the Declaration of Helsinki, we modified the standard water-loading test (drinking 20 ml/kg of water in 30 minutes and collecting urines for 4 hours) by having them exceed their daily water intake by 500 mL the day prior to the test and by 250-500 mL with a light breakfast on the morning of the water-loading test. This modification minimized acute reductions in serum sodium during water-loading. Blood and urine samples were obtained before water-loading, and all urines were collected for the next 4 hours. Blood was drawn at about the fourth hour in 4 patients to determine plasma ADH.
results
All 14 patients with nonedematous hyponatremia, serum sodium <135 mmol/L and FEurate of 4%-11% diluted their urines to <200 mOsm/kg either on a random urine collection (n=8) or after water-loading (n=6) (Tab. I). The Uosms during the water-loading test in patients 1, 2, 3, 7, 8 and 9 are included in Table II . Serum sodium decreased by between 2 and 5 mmol/L after water-loading, and the patients remained clinically unchanged. Plasma ADH levels in patients 3, 7, 8 and 9 were undetectable at <1 pg/mL after water-loading. There was no history of low solute intake to account for the hyponatremia (21) . The baseline studies and comorbidities are summarized in Tables I and III , respectively. Twentyfour-hour urine urate excretion in patients 2, 3, 4, 7, 8 and 9 were 470, 858, 895, 578, 336 and 294 mg, respectively. All patients had normal renal, thyroid and adrenal functions. Nine patients had concentrated urines, and 12 had UNa >20 mmol/L. Nine patients were hypouricemic, with serum urate <4 mg/dL, yet all 14 patients had normal FEurates of 4%-11%. Patients 5, 6, 10, 11,12 and 13 had Uosms <200 mOsm/kg at baseline, and patients 4, 6 and 9 had Uosms of 190,192 and 127, respectively, at a time other than at baseline (Tab. I). Patients 2 and 8 had hyponatremia for over 10 years and failed to respond to water restriction and salt supplementation. Twelve patients were outpatients. RO in patient 9 resolved 7 months after recovery from her comorbid condition. Except for the use of hydrochlorothiazide in 1 patient, none of the medications taken by the patients are known to induce hyponatremia. FEurate was normal in 4 patients despite their being on medications that decrease serum urate and increase FEurate: 3 on losartan and 2 on losartan and Water-loading was performed after increasing usual daily water intake by 500 mL the day before and 250-500 mL on the morning of the water-loading test. Urine collections during the water-loading test are designated as U0, baseline urine before water-loading, followed by successive urines (U1-U6) collected during the water-loading test. # = patient number (which coincides with designated patient numbers in Table I with corresponding Uosm); Uosm = urine osmolality. Comorbid conditions of 14 patients in study and duration of hyponatremia in years in parenthesis. Patient numbers coincide with numbers designated for each patient in Table I . S/P = status post.
atorvastatin (22, 23) . One patient was on hydrochlorothiazide, which decreases FEurate and increases serum urate when in negative salt balance, and conversely increases FEurate and decreases serum urate when hyponatremic (24, 25) .
dIscussIon
RO, type C SIADH, occurs in 36% of patients with SIADH and is associated with a myriad of comorbid conditions (1). Thirteen of our patients were self-sufficient, and 2 had no comorbidities. RO has been reported with tuberculosis, alcoholism, pregnancy, psychogenic polydipsia, gastric, colonic and oat cell carcinomas and in the elderly (26) (27) (28) (29) (30) (31) . RO can last for extended periods of time, resolve spontaneously or after treatment of the comorbid condition (26) . The normal osmostat for ADH secretion appears to be fixed between 275 and 295 mOsm/kg (32) . In RO, the inhibition of ADH secretion occurs at a lower serum osmolality. When serum osmolality decreases below the osmolality at which the osmostat has been reset, the decreasing ADH levels increase free-water excretion and prevent further lowering of serum sodium as long as water intake does not exceed the capacity of the kidneys to excrete free water, as in psychogenic polydipsia. Treatment has been generally unsuccessful because patients with RO remain in salt balance by promptly excreting ingested sodium, and water restriction has been difficult to sustain. Because serum sodium levels usually range between 125 to 135 mmol/L and are protected against severe, symptomatic hyponatremia, they have been traditionally left untreated except to avoid acute ingestion of large volumes of water and treat comorbid conditions (3, (26) (27) (28) (29) (30) (31) . However, bone fractures occurred more frequently in hyponatremic ambulatory elderly with a mean serum sodium of 131 ± 3 mmol/L, at an odds ratio of 4.16 (4) . In another study, falls in the elderly occurred with greater frequency in hyponatremic elderly, with an odds ratio of 67 regardless of the degree of hyponatremia. The increase in falls might have resulted from gait and attention deficits that improved after correction of hyponatremia (6) . Studies on the treatment of RO have been hampered by the limited number of patients and lack of a systematic study of the various regimens that are available to treat hyponatremia, such as any combination of water restriction, salt supplementation, diuretics, demeclocycline or inhibition of V 1 and/or V 2 receptors. The successful use of the vaptans must have included patients with RO. These data suggest that the vaptans might be the preferred choice to treat RO, a syndrome that can be chronic and common in an outpatient setting (9, 10). The diagnosis of RO was made in every nonedematous hyponatremic patient with a normal FEurate, suggesting that a normal FEurate is a good indicator of RO regardless of UNa or serum urate levels. Without randomly collected dilute urine samples, however, the diagnosis of RO can only be made definitively by a water-loading test. The high prevalence of RO legitimizes the question whether all patients suspected of having SIADH should undergo a water-loading test or what the selection criteria are for performing a waterloading test to establish the diagnosis of RO (2, 33). We do not recommend performing a water-loading test in patients with other subtypes of SIADH and RSW and in suspected RO with serum sodium <125 mmol/L. It is also unclear how dilute the urine must be before the diagnosis of RO can be made. We arbitrarily selected a Uosm of <200 mOsm/kg to designate a Uosm that would be more acceptable to make a diagnosis of RO. We do not mean to suggest that this value represents the value at which the osmostat has been reset or the Uosm at which ADH was completely suppressed. The suppression of plasma ADH to undetectable levels <1 pg/mL and the excretion of dilute urines after water-loading are consistent with the diagnosis of RO. Based on the dilute random urines and normal water-loading tests in every nonedematous hyponatremic patient we encountered with a normal FEurate, a normal FEurate appears to be a sensitive indicator of RO in these patients. The answer to whether the diagnosis of RO can rely solely on a normal FEurate without a water-loading test needs to be determined. Although our patients tolerated water-loading, we do not recommend water-loading in nonedematous hyponatremic patients with normal FEurate who lack randomly collected dilute urines. We suggest instituting the usual treatment for euvolemic hyponatremia for such patients. The awareness that RO can be differentiated from other subtypes of SIADH and RSW by a normal FEurate supports our proposal that FEurate is superior to serum urate (11) (12) (13) . Nine of our 14 patients met the criteria for hypouricemia, yet all had a normal FEurate. The greater value of FEurate refines the proposal by Beck that the coexistence of hyponatremia and hypouricemia differentiates SIADH from most other causes of hyponatremia (15) . FEurate is superior to serum urate when evaluating patients with hyponatremia. The present study suggests that patients with RO can be readily identified by a normal FEurate. In other subtypes of SIADH, an elevated FEurate >12% was noted to have a high sensitivity and specificity for SIADH and was superior to fractional excretion of sodium (FENa) or UNa (15) (16) (17) (18) (19) (20) . An increased FEurate has also been reported in RSW, and FEurate can differentiate SIADH from RSW by being persistently increased in RSW and returning to normal after correction of hyponatremia in SIADH (11) (12) (13) (14) . The normal FEurate in psychogenic polydipsia can be distinguished by the excessive water intake (34) . The low to normal FEurate that is seen with hypervolemic hyponatremia, such as with congestive heart failure, cirrhosis, nephrosis or preeclampsia, can be ruled out by the presence of edema. There might be a diagnostic dilemma in patients with hypovolemic hyponatremia and normal kidney function. The low UNa in patients 5 and 10 is highly inconsistent with hypovolemic hyponatremia because of the dilute urine. A low UNa can be observed when salt intake is low in SIADH and RSW (13 depleted subjects with normal kidney function might help to differentiate these patients from those with RO (35) . In summary, RO is a common disorder that is found predominantly in an ambulatory setting and can be identified by a normal FEurate irrespective of the patient's serum urate or UNa. The determination of FEurate is superior to serum urate in the evaluation of patients with nonedematous hyponatremia. The present study supports the high prevalence of RO, provides a simple method of establishing the diagnosis of RO and offers physicians and patients greater comfort and understanding of this relatively benign condition. Patients with RO have been customarily left untreated (26) (27) (28) (29) (30) (31) , but the tendency to treat even mild hyponatremia creates a therapeutic dilemma. Future studies will hopefully test more systematically the effectiveness of water restriction, salt supplementation, diuretics, demeclocycline or the V 1 and/or V 2 receptor inhibitors in RO. In the absence of a dilute random urine, we suggest treating nonedematous hyponatremia in patients with normal FEurate by following guidelines for treating euvolemic hyponatremia without performing a water-loading test. Hypertonic saline should be used to treat symptomatic hyponatremia to increase serum sodium 4-6 mmol/L in 4 hours (8) . The correction of chronic hyponatremia should follow conservative guidelines of increasing serum sodium <10 mmol/L per 24 hours, with slower rates for patients with severe malnutrition and cirrhosis to avoid osmotic demyelination (2, 8) .
